ATC and PDTC are characterized by a very high proliferation rate and tumor invasiveness, driven by concurrent mutations in several pro-proliferative pathways (RAS, WNT, loss of TP53), and strongly activated VEGF/FGF signaling. This evidence concerns the gene VEGFA and neoplasm.